Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,841 | -4,150 | -2,967 | -910 | -2,734 |
| Depreciation Amortization | 595 | 536 | 464 | 53 | 2 |
| Accounts payable and accrued liabilities | -274 | -267 | -114 | -21 | 407 |
| Other Working Capital | -419 | -251 | 224 | -30 | 500 |
| Other Operating Activity | 1,211 | 1,517 | 1,073 | 158 | 70 |
| Operating Cash Flow | $-3,728 | $-2,614 | $-1,319 | $-752 | $-1,755 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2 | -2 | N/A | N/A | -23 |
| Investing Cash Flow | $-2 | $-2 | $N/A | $N/A | $-23 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 721 | 721 | 713 | 721 | 1,986 |
| Other Financing Activity | 6,023 | 6,031 | 1,000 | 0 | 0 |
| Financing Cash Flow | $6,744 | $6,752 | $1,713 | $721 | $1,986 |
| Beginning Cash Position | 207 | 207 | 207 | 207 | N/A |
| End Cash Position | 3,221 | 4,343 | 601 | 177 | 207 |
| Net Cash Flow | $3,014 | $4,135 | $394 | $-31 | $207 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,728 | -2,614 | -1,319 | -752 | -1,755 |
| Capital Expenditure | -2 | -2 | N/A | N/A | -23 |
| Free Cash Flow | -3,730 | -2,616 | -1,319 | -752 | -1,779 |